Kailera Therapeutics, Inc. (KLRA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$112.6M
Cash & Equivalents
$68.3M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$2,838M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07284875 | Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who ... | PHASE3 | Recruiting | 1,800 |
| NCT07284901 | Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | PHASE3 | Recruiting | 1,700 |
| NCT07284979 | Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living Wi... | PHASE3 | Recruiting | 1,200 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.